Postherpetic neuralgia (PHN) is persistent neuropathic pain following shingles, a disease caused by reactivation of varicella-zoster virus. It affects the area supplied by the nerves involved in the original shingles episode, often after the skin lesions have healed. A widely used definition is pain continuing for at least 90 days after the onset of the shingles rash, although definitions vary across studies and clinical settings. PHN is a major complication of shingles and can substantially impair sleep, daily activities, and quality of life.
Cause and mechanism
Varicella-zoster virus causes chickenpox during primary infection. It then remains latent in sensory nerve ganglia, including the dorsal root ganglia near the spinal cord and sensory ganglia of cranial nerves. Reactivation produces shingles, usually with pain and a blistering rash confined to one side of the body.
During shingles, viral activity and inflammation can injure sensory neurons and their nerve fibers. Persistent pain may involve several overlapping mechanisms:
- Abnormal nerve activity: injured sensory neurons can generate spontaneous electrical signals or respond excessively to stimulation.
- Loss of normal sensory input: damage to nerve fibers can produce numbness while also disrupting normal regulation of pain signals.
- Altered central processing: changes in the spinal cord and other parts of the central nervous system can amplify pain and reduce inhibitory control.
These processes explain why pain can persist after the rash has resolved. Established PHN is not, by itself, evidence of continued viral replication, a new shingles episode, or ongoing contagiousness.
Symptoms and distribution
Pain is usually located in the same skin territory as the preceding shingles rash. This territory is called a dermatome: an area supplied predominantly by a particular spinal nerve root. The trunk is commonly affected, although PHN can also involve the face, scalp, or limbs.
Symptoms can include:
- Constant burning, aching, or throbbing pain.
- Intermittent stabbing, shooting, or electric-shock-like pain.
- Pain from normally harmless contact, such as clothing touching the skin.
- An exaggerated response to painful stimulation.
- Tingling, numbness, or persistent itching.
Pain caused by a normally nonpainful stimulus is termed allodynia. It may coexist with reduced sensitivity in the same area, reflecting the complex effects of nerve injury.
PHN can interfere with dressing, bathing, movement, and social activity. Insomnia, fatigue, and depression may accompany persistent symptoms. These effects contribute to reduced health-related quality of life, beyond the intensity of pain alone.
Frequency and risk factors
Reported frequency varies with the age of the population, the definition of PHN, and the duration of follow-up. Estimates therefore cannot be compared reliably without considering how persistent pain was measured.
Older age is the strongest established risk factor. PHN is uncommon in children and young adults, while its frequency and persistence increase substantially in older adults. Other associated factors include severe pain during the acute shingles episode, an extensive rash, and pain preceding the rash.
Conditions associated with immunosuppression increase the risk of shingles and its complications. Their relationship with PHN also depends on age, the underlying condition, and the severity of the acute infection.
Diagnosis
Diagnosis is usually clinical, based on a history of shingles followed by persistent pain in the corresponding area. A medical history establishes the timing of the rash and pain, while a physical examination assesses residual skin changes and altered sensation.
No routine blood test or imaging study confirms PHN. Testing is generally directed at alternative explanations when the presentation is atypical. The differential diagnosis includes nerve-root compression, other peripheral nerve disorders, musculoskeletal pain, and local skin disease.
Definitions based on time are important. Pain during acute shingles is not automatically PHN. Some classifications distinguish acute pain, subacute pain, and pain persisting beyond approximately three months. Whether that interval is measured from rash onset or healing can change reported case numbers.
Treatment and its limitations
Treatment aims to reduce pain and its effects on function and sleep. Available therapies do not consistently reverse the underlying nerve injury, and complete pain relief is not assured.
Medicines and topical treatments
Established treatments include gabapentin and pregabalin, which modify signaling through voltage-gated calcium channels, and certain tricyclic antidepressants, which influence pain-modulating pathways. Their analgesic effects are distinct from their uses for seizures or depression.
Topical lidocaine can reduce localized pain with relatively limited systemic exposure. High-concentration capsaicin patches act on pain-sensing nerve endings and are administered in clinical settings; application can itself cause substantial discomfort.
Treatment selection is influenced by adverse effects and coexisting conditions. Gabapentinoids can cause dizziness, sleepiness, and edema, and their dosing depends on kidney function. Tricyclic antidepressants can cause anticholinergic effects, sedation, and cardiovascular adverse effects.
Opioids can reduce pain in some cases, but dependence, sedation, constipation, and respiratory depression limit their role in long-term treatment. Ordinary nonopioid analgesics often provide insufficient relief for established neuropathic pain.
Other approaches
Psychological interventions, including cognitive behavioral therapy, can address pain-related distress and interference with daily life. Their purpose is not to imply that nerve pain has a psychological origin.
Nerve blocks, neuromodulation, and other interventional procedures have been studied for difficult-to-treat PHN. Evidence varies by procedure, and long-term benefit is not consistently established.
Prevention and course
Shingles vaccination reduces the risk of shingles and consequently the burden of PHN. Recombinant zoster vaccines have demonstrated protection against both outcomes. Vaccination is preventive rather than a treatment for established PHN.
During acute shingles, antiviral drugs reduce viral replication and improve aspects of the acute illness. Their ability to prevent PHN is less certain than their effects on acute shingles. Corticosteroids have not been shown to reliably prevent PHN.
Symptoms often diminish over time, but recovery is variable. Some cases resolve over months, while others persist for years. Older age and greater initial pain severity are associated with a less favorable course. Persistent symptoms do not necessarily indicate progressive nerve damage or recurrent infection.